C1q/TNF-related Protein 9 (CTRP 9) Level in Preeclamptic Obese and Non-obese Pregnancies

Diyarbakir Women's and Children's Diseases Hospital

Status: Completed

Conditions: Pre-Eclampsia; Obesity; Endocrine

Treatments: Diagnostic Test: Blood test

Study type: Interventional

Funder types: Other

Identifiers

NCT03650790

DiyarbakirWCDH

Details and patient eligibility

About

The complement C1q tumor necrosis factor-associated protein-9 (CTRP-9), which is responsible for regulating cardiovascular and metabolic functions, increases vascular relaxation by pathway dependent on AMPK / endothelial nitric oxide synthesis (eNOS). The aim of this study was to investigate CTRP-9 levels in pregnant women with preeclampsia.

Full description

The most important reason for the development of preeclampsia is the problem of trophoblastinvasion and consequent formation and development of placenta is not healthy

Cytokines are regulatory molecules that have effects on cell functions.Cytokines are molecules that also regulate endothelial functions. Placenta formation and widespread endothelial damage are under the influence of cytokines.

Therefore, there may be important links between impairment or imbalance in cytokine release and function and the formation of preeclampsia.Nitric oxide (NO) is a biologic enzyme that is synthesized by nitric oxide synthase (NOS) from the amino acid of L-arginine and exists in all mammals.

e(NOS) is the three isoforms of NO. It is known that NO is a major vasodilator of pregnancy, inhibiting platelet and leukocyte aggregation.There was a decrease in NO levels in preeclamptic patients.

The CqP / TNF Binding Protein (CTRP) family consists of 15 members, and is synthesized in many organs outside the body of fat.CTRP9 is predominantly excreted in fat tissue, and levels in circulation are reduced in patients with diabetes and obesity.Many studies have shown that CTRP9 exerts beneficial effects on metabolic and cardiovascular homeostasis.

CTRP9 increases vascular relaxation in the AMPK / endothelial nitric oxide synthase (eNOS) dependent pathway. CTRP9 has also been reported to reduce inflammatory responses in endothelial cells via the AMPK-dependent pathway.

Vasorelaxation due to CTRP9 is endothelium-dependent and NO-mediated. CTRP9, directly acting on smooth muscle, is indirectly or indirectly associated with NO production in the vascular endothelial layer by stimulating vasorelaxial molecular production by endothelial cells.

Enrollment: 120 patients

Sex: Female

Ages: 15 to 40 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Pregnant women who are ages 15-40
• BMI ≥35 kg/m2 and BMI<25 KG/m2 pregnants
• The clinical diagnosis of preeclampsia will follow the current criteria outlined by ACOG 10
• > 20 th weeks of pregnancy

Exclusion criteria

• A previously known chronic metabolic disease (diabetes, pregestational dyslipidemia, hypertension,)
• collagen vascular diseases,
• inflammatory bowel disease
• chronic inflammatory conditions,

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

120 participants in 3 patient groups

preeclamptic obese pregnancy

Active Comparator group

Description:

CTRP 9 level will be assessed by 40 obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.

Treatment:

Diagnostic Test: Blood test

preeclamptic non-obese pregnancy

Active Comparator group

Description:

CTRP 9 level will be assessed by 40 non-obese preeclamptic gestational ELISA methods that meet the latest ACOG criteria.

Treatment:

Diagnostic Test: Blood test

normal pregnancy

Active Comparator group

Description:

CTRP 9 level will be assessed by 40 normal gestational ELISA methods

Treatment:

Diagnostic Test: Blood test